Overview Phase 2a Study of HPG1860 in Subjects With NASH Status: Recruiting Trial end date: 2023-03-01 Target enrollment: Participant gender: Summary This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH. Phase: Phase 2 Details Lead Sponsor: Hepagene (Shanghai) Co., Ltd.